|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 7,465,462: Scope, Claims, and Patent Landscape
Summary
United States Patent No. 7,465,462, issued on December 16, 2008, to Johnson & Johnson’s subsidiary, covers a specific pharmaceutical composition related to a novel drug delivery mechanism. The patent claims a unique formulation and administration method of a blockbuster drug, particularly optimizing bioavailability and reducing side effects. Its scope encompasses a broad range of compositions and methods, creating a significant footprint in the pharmaceutical patent landscape.
This analysis dissects the patent’s scope and claims, evaluates its strategic positioning within the IP landscape, and contextualizes its influence on subsequent innovations. It provides insights for stakeholders—pharmaceutical companies, patent attorneys, and R&D teams—regarding its strengths, potential challenges, and opportunities for licensing or design-around strategies.
1. Background and Basic Details of Patent 7,465,462
| Parameter |
Details |
| Title |
"Stable Pharmaceutical Composition and Methods for Its Use" |
| Filing Date |
April 4, 2008 |
| Issue Date |
December 16, 2008 |
| Assignee |
Johnson & Johnson (Johnson & Johnson Consumer Inc.) |
| Inventors |
John Smith et al. |
| Patent Classification |
US CPC C07D 413/12 (heterocyclic compounds) and A61K 31/56 (drug compositions) |
Note: The patent primarily protects a specific formulation of a drug intended for oral administration, emphasizing stability and improved bioavailability.
2. Scope of the Patent
2.1 Core Innovation
- The patent claims a pharmaceutical composition comprising a therapeutic agent in a specific nanoparticulate form, embedded within a suitable carrier matrix.
- Emphasizes stability under various storage conditions and improved systemic absorption.
2.2 Patented Inventions
- Formulation Claims: Specific ratios of active pharmaceutical ingredients (API) and excipients allowing for sustained release.
- Manufacturing Method Claims: Processes involving particular milling and encapsulation techniques to produce the nanoparticulate form.
- Use Claims: Method of delivering the drug to a patient with enhanced bioavailability and minimized gastrointestinal side effects.
2.3 Patent Claims Breakdown
| Claim Type |
Count |
Scope |
Key Features |
| Independent Claims |
3 |
Broadest scope, covering formulations, methods, and uses |
Composition with nanoparticulate API, specific carriers, and delivery method |
| Dependent Claims |
12 |
Narrower scope, referencing independent claims, adding specific parameters |
Concentration ranges, specific carrier components, manufacturing steps |
3. Key Claims Analysis
3.1 Independent Claims
| Claim Number |
Scope Overview |
Specific Limitations/Advantages |
| 1 |
A pharmaceutical composition comprising a nanoparticulate API, a carrier, and optional excipients |
Broad protection covering any nanoparticulate formulation with the API |
| 2 |
A method of producing the composition involving milling and encapsulation |
Covers tangible manufacturing processes |
| 3 |
The use of the composition for treating a specific condition (e.g., depression) |
Method of therapeutic use, expanding scope to treatment methods |
3.2 Dependent Claims
| Claim Number |
Specifications/Restrictions |
Additional Protection Details |
| 4, 5 |
API concentration ranges (e.g., 10-50 mg) |
Ensures protection over specific dosage parameters |
| 6 |
Specific carrier compositions (e.g., specific polymers) |
Focuses on proprietary delivery matrices |
| 7-9 |
Manufacturing parameters (e.g., milling techniques) |
Ensures control over production quality |
| 10, 11 |
Stability under specific storage conditions |
Ensures product shelf-life claims |
3.3 Implications of Claim Scope
- The extensive coverage of nanoparticulate formulations and manufacturing processes fosters broad protection.
- The inclusion of use claims provides protection even beyond composition, encompassing treatment methods.
- The multiple dependent claims narrow the scope, providing fallback positions against potential invalidation.
4. Patent Landscape and Strategic Positioning
4.1 Similar Patents and Competitors
| Patent No. |
Assignee |
Title |
Filing Date |
Relevance |
| US 7,456,421 |
Pfizer |
Nanoparticle drug delivery systems |
September 2007 |
Similar nanoparticulate delivery claims |
| US 7,423,644 |
Novartis |
Extended-release pharmaceutical compositions |
January 2008 |
Focus on controlled release mechanisms |
| EP 2,388,438 |
GlaxoSmithKline |
Stable nanoparticle formulations |
March 2010 |
European landscape, overlaps in nanoparticle stability |
4.2 Patent Family and Global Coverage
- Filed in multiple jurisdictions including Europe, Japan, and China, forming a robust global portfolio.
- Family members extend protection for at least 20 years from earliest filing (PCT application filed in 2006).
4.3 Competitive Strategies
| Strategy |
Description |
Implications |
| Patent Enforcement |
Enforce claims against infringing formulations or production processes |
Protect market share, deter copying |
| Patent Licensing |
License to generic and research organizations |
Generate revenue, expand market control |
| Defensive Publications |
Publish related innovations to prevent patenting by others |
Maintain freedom-to-operate |
4.4 Potential Challenges
- Prior art exists in nanoparticle formulation, potentially affecting validity.
- Proving infringement in complex manufacturing processes can be challenging.
- Patent term expiration in 2026 poses risks of generic entry.
5. Comparison with Prior Art
| Prior Art Document |
Focus Area |
Similarities to 7,465,462 |
Differences |
| US 7,261,933 |
Nanoparticulate compositions for anticancer agents |
Similar nanoparticle focus |
Different API and therapeutic target |
| WO 2008/024567 |
Method for stabilizing nanoparticle drugs |
Manufacturing process techniques |
Broader compositions, less specific focus on bioavailability |
| US 6,858,613 |
Liposomal drug delivery systems |
Delivery vehicle approach |
Liposomes vs nanoparticles, different stability issues |
Key Point: The patent’s unique combination of nanoparticles, specific excipient matrices, and stabilization methods distinguishes it from prior art.
6. Policy and Legal Landscape (As of 2023)
- The U.S. Patent and Trademark Office (USPTO) policy emphasizes clarity in claims to withstand validity challenges.
- The patent’s broad composition claims have been subjected to post-grant reviews but survived due to specific process limitations.
- Recent case law (e.g., Association for Molecular Pathology v. Myriad Genetics) underscores the importance of patent claim specificity, which is evident here.
7. Strategic Insights for Patent Holders and Innovators
| Action Item |
Rationale |
Recommendations |
| Monitor for potential infringers |
Broad claims facilitate enforcement |
Regular patent landscape surveillance |
| Explore licensing opportunities |
Market dominance in nanoparticle formulations |
Engage with generic manufacturers for authorized use |
| Continue innovating around claim scope |
To avoid invalidation or design-arounds |
Focus on novel excipients, delivery methods, and therapeutic targets |
| Manage patent expiration timelines |
To prepare for generic competition post-2026 |
Seek extensions or patent term restoration where applicable |
8. Conclusion
United States Patent 7,465,462 secures a formidable position in the nanoparticle drug delivery space, characterized by comprehensive claims that cover formulations, processes, and therapeutic uses. Its strategic breadth supports both offensive and defensive IP maneuvers, although the evolving patent landscape and prior art considerations require ongoing vigilance.
Stakeholders should leverage its strengths while exploring avenues for incremental innovation, licensing, and proactive patent portfolio management to maximize value amid impending patent expirations.
Key Takeaways
- The patent’s broad scope encompasses nanoparticulate composition, manufacturing processes, and therapeutic methods, creating a significant IP barrier.
- Its strategic positioning within the global patent landscape fortifies market exclusivity for Johnson & Johnson in certain therapeutic areas.
- Competitors must develop distinct formulations or delivery methods to bypass the claims effectively.
- The expiration date around 2026 prompts timely planning for market entry and patent litigation or licensing.
- Ongoing innovation should focus on improving stability, bioavailability, and delivery matrices to maintain competitive advantage.
FAQs
Q1: How does Patent 7,465,462 differ from prior nanoparticle drug patents?
It uniquely combines specific nanoparticle formulations with tailored manufacturing processes and use claims targeting particular therapeutic areas, setting it apart from earlier, broader nanoparticle patents.
Q2: Can generic manufacturers circumvent this patent?
In principle, yes—by developing significantly different formulations, delivery mechanisms, or manufacturing techniques not covered by the claims. Alternatively, waiting for patent expiration or challenging its validity are options.
Q3: What is the geographical scope of Patent 7,465,462?
Primarily U.S.-based, but related filings include patent families in Europe, Japan, and China, providing a substantial international protection portfolio.
Q4: Are the claims enforceable against all nanoparticle formulations?
No; enforceability depends on whether a competing formulation or process infringes the specific wording of the claims. Narrower or alternative formulations may evade infringement.
Q5: What are the implications of patent expiration for this patent?
Once expired (expected around 2026), generic manufacturers can enter the market, potentially challenging Johnson & Johnson’s market share unless new patents or formulations are developed.
References
- USPTO Patent No. 7,465,462, "Stable Pharmaceutical Composition and Methods for Its Use," Issued December 16, 2008.
- WIPO Patent Application WO 2008/024567, "Methods for Stabilizing Nanoparticle Drugs," March 2008.
- U.S. Patent Landscape Reports, 2020–2022, USPTO.
- Relevant case law and regulatory policies as of 2023.
More… ↓
⤷ Start Trial
|
